|
Market Closed -
BME
18:35:16 09/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 58.05 EUR | -0.17% |
|
+1.13% | -8.58% |
| 10-05 | Spanish stocks - Factors to watch on Oct 5 | RE |
| 07-23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 2,969 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -8.59% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 2,960 | 2,896 | 2,783 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -9.52% | -2.16% | -3.91% |
| P/E | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 19.6x | 17.2x | 13.9x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 3.87x | 3.34x | 2.86x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | 2.56x | 1.2x | 0.6x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 3.84x | 3.33x | 3.04x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 3.82x | 3.25x | 2.85x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 15x | 11.3x | 8.91x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 18x | 13x | 10.1x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 23.6x | 23.7x | 16.8x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 4.25% | 4.23% | 5.97% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.9737 | 1.161 | 1.361 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.68% | 2% | 2.34% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 2.96 | 3.37 | 4.164 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 32.9% | 34.5% | 32.7% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 774.1 | 892.4 | 978 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 197.6 | 257.3 | 312.3 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 164.4 | 222.4 | 275.8 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 146.2 | 172.9 | 213.8 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -8.499 | -72.51 | -185.6 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 58.05 | 58.05 | 58.05 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,143 | - | - |
| Announcement Date | 2/23/22 A | 2/21/23 A | 2/27/24 A | 2/25/25 A | 2/24/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.61x | 3.82x | 14.98x | 1.68% | 3.32B | |
| 33.55x | 12.18x | 25.21x | 0.58% | 1,051B | |
| 29.08x | 6.43x | 18.37x | 2.04% | 630B | |
| 35.19x | 8.13x | 16.76x | 2.51% | 489B | |
| 105.8x | 5.93x | 25.27x | 2.34% | 359B | |
| 19.31x | 4.72x | 11.72x | 2.8% | 344B | |
| 20.06x | 5.27x | 12.98x | 3.02% | 272B | |
| 20.57x | 4.22x | 12.06x | 2.1% | 246B | |
| 26.34x | 6.83x | 12.21x | 2.43% | 224B | |
| -45.84x | 6.75x | 26.31x | 2.18% | 187B | |
| Average | 26.37x | 6.43x | 17.59x | 2.17% | 380.7B | |
| Weighted average by Cap. | 32.40x | 7.84x | 19.33x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
